Brief: Sanofi Pasteur strucks licence agreement with SK Chemicals
12/02/2018 11:29
Feb 12 (Reuters) - Sanofi SASY.PA :
* SK Chemicals 285130.KS announces license agreement with
Sanofi
Pasteur in cell culture technology for potential use in Sanofi's
strategic broadly protective influenza vaccine development
program
* agreement between SK Chemicals and Sanofi Pasteur is
eligible
for payment of up to $155 million when achieving all milestones
Further company coverage: SASY.PA
((Paris Newsroom))
Recent news on SK Chemicals
See all newsBrief: Sk Chemicals Co Aims 11% Operating Margin By 2030
Brief: Sk Chemicals Co Q1 Consolidated Operating. Loss 18.9 Billion Won Versus 24.3 Billion Won Profit A Year Ago
Brief: Sk Chemicals Sells 220 Billion Won Exchangeable Bonds
Brief: SK Chemicals Partners with Durmont to Supply Sustainable Materials to Global Auto Brands
South Korea's mountain of plastic waste shows limits of recycling (updated)